Using Y90-PET-CT scans after liver cancer treatment
Introduction to the Clinical Workflow of Y90-PET-CT Post-therapy Scans to Patients Undergoing Y90-microspheres Radioembolisation Therapy
This study is testing a new type of scan to see if it can better show how well a liver cancer treatment is working for patients receiving Y90 radioembolisation therapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | The Christie NHS Foundation Trust Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Manchester) |
| Trial ID | NCT06123676 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with liver cancer or liver metastasis undergoing Y90 radioembolisation therapy, where yttrium-90 microspheres are infused into the liver to target tumors. The primary goal is to introduce and optimize a Y90-PET-CT scanning protocol to assess the delivery of the radioactive treatment to the target lesions. By comparing the quality of images obtained from Y90-PET-CT scans to traditional Y90-bremsstrahlung-SPECT scans, the study aims to provide more accurate information regarding the success of the therapy. Additionally, the study will implement post-therapy dosimetry using the optimized imaging to enhance patient management.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-85 who are undergoing Y90-microspheres therapy for liver cancer.
Not a fit: Patients with claustrophobia or those unable to comply with the scanning protocol may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved assessment of treatment effectiveness for liver cancer patients.
How similar studies have performed: While the use of Y90-PET-CT is a novel approach in this context, similar imaging techniques have shown promise in enhancing treatment assessment in other cancer therapies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients undergoing liver treatment Y90-Microspheres therapy. * Male or female * Aged 18-85 years Exclusion Criteria: A participant will not be eligible for inclusion in this study if any of the following criteria apply: * History of, or suffers from, claustrophobia or participant feels unable to lie flat and still on their back for a period of up to 45 minutes in the scanner; o Priority will be given to their current clinical care scan Y-90-bremsstrahlung-SPECT * In the opinion of the clinical team, they are unlikely to comply with the study protocol and restrictions that it imposes (i.e. patient uncomfortable to withstand a double scan on the day); Female participants of childbearing potential must confirm they are not pregnant (a strict requisite before 90Y-therapy anyway).
Where this trial is running
Manchester
- The Christie NHS - Nuclear Medicine Department — Manchester, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Heather Williams
- Email: heather.williams34@nhs.net
- Phone: 01619187118
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.